Which of the following adverse effect of levodopa is not blocked by carbidopa?
**Core Concept**
The use of levodopa in the treatment of Parkinson's disease is often accompanied by the administration of carbidopa, a decarboxylase inhibitor that prevents the peripheral conversion of levodopa to dopamine. This is crucial to increase the bioavailability of levodopa and minimize its peripheral side effects.
**Why the Correct Answer is Right**
Levodopa is metabolized by aromatic L-amino acid decarboxylase (AADC) in both the central nervous system (CNS) and the peripheral tissues. Carbidopa competitively inhibits AADC, thereby reducing the peripheral conversion of levodopa to dopamine, but it does not cross the blood-brain barrier. However, the peripheral conversion of levodopa to dopamine is responsible for nausea, vomiting, and orthostatic hypotension. The CNS conversion of levodopa to dopamine is responsible for the therapeutic effect. **Option C: Dyskinesias** is not blocked by carbidopa because dyskinesias are a direct result of the CNS conversion of levodopa to dopamine, which is not affected by carbidopa.
**Why Each Wrong Option is Incorrect**
**Option A:** Nausea and vomiting are indeed peripheral effects of levodopa and are blocked by carbidopa.
**Option B:** Orthostatic hypotension is also a peripheral effect of levodopa and is blocked by carbidopa.
**Option D:** Flushing is not a well-documented side effect of levodopa.
**Clinical Pearl / High-Yield Fact**
Carbidopa-levodopa combination is a classic example of a prodrug combination, where the addition of a decarboxylase inhibitor (carbidopa) enhances the bioavailability of the parent drug (levodopa) and reduces its peripheral side effects.
**Correct Answer:** C. Dyskinesias